Menopause and Mitochondria
Open accessThe DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
Metabolic derangements and oxidative stress are early events in Alzheimer’s disease pathogenesis. Multifaceted effects of estrogens include improved cerebral metabolic profile and reduced oxidative stress through actions on mitochondria, suggesting that a woman’s endogenous and exogenous estrogen exposures during midlife and in the late postmenopause might favorably influence Alzheimer risk and symptoms. This prediction finds partial support in the clinical literature. As expected, early menopause induced by oophorectomy may increase cognitive vulnerability; however, there is no clear link between age at menopause and Alzheimer risk in other settings, or between natural menopause and memory loss. Further, among older postmenopausal women, initiating estrogen-containing hormone therapy increases dementia risk and probably does not improve Alzheimer’s disease symptoms. As suggested by the “critical window” or “healthy cell” hypothesis, better outcomes might be expected from earlier estrogen exposures. Some observational results imply that effects of hormone therapy on Alzheimer risk are indeed modified by age at initiation, temporal proximity to menopause, or a woman’s health. However, potential methodological biases warrant caution in interpreting observational findings. Anticipated results from large, ongoing clinical trials (Early versus Late Intervention Trial with Estradiol [ELITE]; Kronos Early Estrogen Prevention Study [KEEPS]) will help settle whether midlife estrogen therapy improves midlife cognitive skills but not whether midlife estrogen exposures modify late life Alzheimer risk. Estrogen effects on mitochondria adumbrate the potential relevance of estrogens to Alzheimer’s disease. However, laboratory models are inexact embodiments of Alzheimer pathogenesis and progression, making it difficult to surmise net effects of estrogen exposures. Research needs include better predictors of adverse cognitive outcomes, biomarkers for risks associated with hormone therapy, and tools for monitoring brain function and disease progression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Alzheimer Disease in the US Population: Prevalence Estimates Using the 2000 Census
Hebert, L. E., Scherr, P. A., Bienias, J. L., Bennett, D. A., & Evans, D. A. (2003) · Archives of Neurology · doi:10.1001/archneur.60.8.1119 · Cited by 2,168 · cited 1×
“Alzheimer’s disease, by far the most common cause of dementia occurring later in life, affects an estimated 2.5–4.5 million older Americans (Hebert et al., 2003; Plassman et al., 2007).”
BackgroundInfluentialMixed brain pathologies account for most dementia cases in community-dwelling older persons
Schneider, J. A., Arvanitakis, Z., Bang, W., & Bennett, D. A. (2007) · Neurology · doi:10.1212/01.wnl.0000271090.28148.24 · Cited by 1,992
Prevalence of Dementia in the United States: The Aging, Demographics, and Memory Study
Plassman, B. L., Langa, K. M., Fisher, G. G., Heeringa, S. G., Weir, D. R., Ofstedal, M. B., Burke, J. R., Hurd, M. D., Potter, G. G., Rodgers, W. L., et al. (2007) · Neuroepidemiology · doi:10.1159/000109998 · Cited by 1,932 · cited 1×
“Alzheimer’s disease, by far the most common cause of dementia occurring later in life, affects an estimated 2.5–4.5 million older Americans (Hebert et al., 2003; Plassman et al., 2007).”
BackgroundInfluentialOxidative Damage Is the Earliest Event in Alzheimer Disease
Nunomura, A., Perry, G., Aliev, G., Hirai, K., Takeda, A., Balraj, E. K., Jones, P. K., Ghanbari, H., Wataya, T., Shimohama, S., et al. (2001) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/60.8.759 · Cited by 1,885 · cited 1×
“Indeed, oxidative stress is an early event in Alzheimer pathogenesis (Nunomura et al., 2001).”
BackgroundPostmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause
Rossouw, J. E., Prentice, R. L., Manson, J. E., Wu, L., Barad, D., Barnabei, V. M., Ko, M., LaCroix, A. Z., Margolis, K. L., & Stefanick, M. L. (2007) · JAMA · doi:10.1001/jama.297.13.1465 · Cited by 1,741
ABAD Directly Links Aß to Mitochondrial Toxicity in Alzheimer's Disease
Lustbader, J. W., Cirilli, M., Lin, C., Xu, H. W., Takuma, K., Wang, N., Caspersen, C., Chen, X., Pollak, S., Chaney, M., et al. (2004) · Science · doi:10.1126/science.1091230 · Cited by 1,303
Androgen Levels in Adult Females: Changes with Age, Menopause, and Oophorectomy
Davison, S. L., Bell, R., Donath, S., Montalto, J. G., & Davis, S. R. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-0212 · Cited by 998 · cited 1×
“In addition to loss of these gonadal steroids, surgical menopause is also accompanied by reduced levels of testosterone (Davison et al., 2005).”
BackgroundRocca, W. A., Bower, J. H., Maraganore, D. M., Ahlskog, J. E., Grossardt, B. R., de Andrade, M., & Melton, L. J. (2007) · Neurology · doi:10.1212/01.wnl.0000276984.19542.e6 · Cited by 827
Rates and risk factors for dementia and Alzheimer’s disease: Results from EURODEM pooled analyses
Launer, L. J., Andersen, K., Dewey, M. E., Letenneur, L., Ott, A., Amaducci, L. A., Brayne, C., Copeland, J. R. M., Dartigues, J.-F., Kragh-Sorensen, P., et al. (1999) · Neurology · doi:10.1212/wnl.52.1.78 · Cited by 758 · cited 2×
“Studies from Europe (Launer et al., 1999) but not from the United States (Edland et al.”
Background
Cited by
Estrogen Effects on Cognitive and Synaptic Health Over the Lifecourse
Hara, Y., Waters, E. M., McEwen, B. S., & Morrison, J. H. (2015) · Physiological Reviews · doi:10.1152/physrev.00036.2014 · Cited by 470
Rocca, W. A., Grossardt, B. R., & Shuster, L. T. (2011) · Brain Research · doi:10.1016/j.brainres.2010.10.031 · Cited by 283
“However, these trials focused on the effects of ET initiated many years after the onset of natural or surgical menopause, and the discrepancy between the WHI results and observational data may be explained by the timing of initiation of estrogen (Manson et al., 2006; Siegfried, 2007; Brinton, 2008; Rocca et al., 2008;…”
BackgroundInfluentialMinireview: translational animal models of human menopause: challenges and emerging opportunities
Diaz Brinton, R. (2012) · Endocrinology · doi:10.1210/en.2012-1340 · Cited by 272
Roles for Oestrogen Receptor β in Adult Brain Function
Handa, R. J., Ogawa, S., Wang, J. M., & Herbison, A. E. (2012) · Journal of Neuroendocrinology · doi:10.1111/j.1365-2826.2011.02206.x · Cited by 97
Mitochondrial and sex steroid hormone crosstalk during aging
Velarde, M. C. (2014) · Longevity & Healthspan · doi:10.1186/2046-2395-3-2 · Cited by 96
“While it remains unclear what mechanisms regulate this contradictory effect of estrogen on mitochondrial ROS production, the contribution of damaged versus healthy cell on estrogen action is consistent with the critical window and healthy cell hypothesis of estrogen replacement therapy [22,100].”
Background
Metadata
- Authors
- Henderson, V. W., & Brinton, R. D.
- Venue
- Progress in Brain Research
- Publisher
- Elsevier
- Published
- 2010
- Volume
- 182
- Pages
- 77-96
- ISSN
- 0079-6123 (ISSN-L)
- OpenAlex
- W158881778
- Cited by
- 79
- References
- 20
- FWCI
- 50.16
- Type
- book chapter
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Menopause and Mitochondria. https://app.cochat.ai/papers/10.1016/s0079-6123(10)82003-5
- The paper
- Henderson, V. W., & Brinton, R. D. (2010). Menopause and Mitochondria. Progress in Brain Research. https://doi.org/10.1016/s0079-6123(10)82003-5
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.